These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 27966023)
1. Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study. Hansen PB; Penkowa M Support Care Cancer; 2017 Apr; 25(4):1279-1289. PubMed ID: 27966023 [TBL] [Abstract][Full Text] [Related]
2. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631 [TBL] [Abstract][Full Text] [Related]
3. The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT). Świerzko AS; Michalski M; Sokołowska A; Nowicki M; Eppa Ł; Szala-Poździej A; Mitrus I; Szmigielska-Kapłon A; Sobczyk-Kruszelnicka M; Michalak K; Gołos A; Wierzbowska A; Giebel S; Jamroziak K; Kowalski ML; Brzezińska O; Thiel S; Jensenius JC; Kasperkiewicz K; Cedzyński M Front Immunol; 2018; 9():2153. PubMed ID: 30294330 [TBL] [Abstract][Full Text] [Related]
4. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670 [TBL] [Abstract][Full Text] [Related]
16. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375 [TBL] [Abstract][Full Text] [Related]
17. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F; Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196 [TBL] [Abstract][Full Text] [Related]
18. Anakinra: efficacy in the management of fever during neutropenia and mucositis in autologous stem cell transplantation (AFFECT-2)-study protocol for a multicenter randomized double-blind placebo-controlled trial. de Mooij CEM; van Groningen LFJ; de Haan AFJ; Biemond BJ; Bakker M; van der Velden WJFM; Blijlevens NMA Trials; 2020 Nov; 21(1):948. PubMed ID: 33225965 [TBL] [Abstract][Full Text] [Related]
19. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Costa LJ; Landau HJ; Chhabra S; Hari P; Innis-Shelton R; Godby KN; Hamadani M; Tamari R; Anderton K; Dixon P; Giralt SA Biol Blood Marrow Transplant; 2018 Jul; 24(7):1379-1385. PubMed ID: 29410301 [TBL] [Abstract][Full Text] [Related]
20. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Sivaraj D; Bacon W; Long GD; Rizzieri DA; Horwitz ME; Sullivan KM; Kang Y; Li Z; Chao NJ; Gasparetto C Bone Marrow Transplant; 2018 Jan; 53(1):34-38. PubMed ID: 29084203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]